The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Molecular Imaging To Advance Treatment Of Dementia
Funder
National Health and Medical Research Council
Funding Amount
$412,419.00
Summary
Molecular imaging using a scan technique called positron emission tomography, enables detection and measurement of specific pathological features of disease such as the amyloid plaques of Alzheimer’s disease. This project will develop this technology for other aspects of brain disorders including dementias, Parkinson’s disease, traumatic brain injury and schizophrenia and use it to assist development of therapies and improve clinical diagnosis nation wide.
Molecular Imaging Of Cancers With Copper And Zirconium Radiopharmaceuticals
Funder
National Health and Medical Research Council
Funding Amount
$466,475.00
Summary
This research aims to develop new imaging agents to assist in the diagnosis of breast cancer. This research will advance knowledge in the areas of chemistry, biotechnology and diagnostic imaging.
The Use Of Positron Emission Tomography (PET), Novel Immune And Microbiological Biomarkers To Improve The Diagnosis And Prognostication Of Giant Cell Arteritis
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Giant cell arteritis (GCA) is an inflammatory condition of blood vessels. Diagnosing the condition and predicting which patients will develop complications is challenging. Undiagnosed, a significant proportion of patients experience sudden onset, permanent blindness. Our study aims to improve the diagnosis and risk assessment of patients with suspected GCA by following a group of 65 patients for two years with serial scans, blood tests and clinical reviews.
Optimizing Lung Cancer Diagnostic And Staging Pathways Through The Innovative Use Of Thoracic Imaging
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
This research aims to simplify the initial work-up for lung cancer diagnosis. Currently most patients undergo complex investigations and multiple biopsies. Common imaging technology e.g. ultrasound, PET and CT scans may help choose the best and least invasive biopsy procedure. My research will explore this through three complementary studies. If positive, >10000 Australians with lung cancer will benefit each year, and the majority of them will only have to undergo one biopsy procedure.
A new scan called PiB PET shows the build up of amyloid protein deposits in the brain in all patients with Alzheimer's disease (AD) but also in 30% of normal elderly persons. This study will track the build up of amyloid and clinical progress in 280 elderly Australians to confirm that this scan can detect AD before symptoms and investigate factors that influence this build up and its damaging effects on memory and thinking. Early detection of Alzheimer's disease will assist accurate diagnosis an ....A new scan called PiB PET shows the build up of amyloid protein deposits in the brain in all patients with Alzheimer's disease (AD) but also in 30% of normal elderly persons. This study will track the build up of amyloid and clinical progress in 280 elderly Australians to confirm that this scan can detect AD before symptoms and investigate factors that influence this build up and its damaging effects on memory and thinking. Early detection of Alzheimer's disease will assist accurate diagnosis and the development of treatment.Read moreRead less
The Development Of Innovative Multiplexed Molecular Imaging Technology Targeting Improved Diagnostic Imaging Of Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$403,599.00
Summary
Glioblastoma Multiforme (GBM) is extremely invasive and the most lethal of all primary brain tumours. To optimise treatment planning, we propose to develop novel Multiplexed Molecular Imaging (MMI) technology employing the latest PET-MRI hybrid imaging technology. Our strategy targets the development of new F19 MRI MI agents for measuring tumour infiltration that can be multiplexed with F18 PET hypoxia tracers. Our MI agents can also act as conjugative vehicles for drug delivery.
The Australian, Imaging, Biomarkers And Lifestyle Study Of Ageing (AIBL) Phase III - Facilitating Early Intervention In Preclinical Alzheimer's Disease.
Funder
National Health and Medical Research Council
Funding Amount
$733,653.00
Summary
Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to ....Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to prevent dementia.Read moreRead less
This Fellowship will focus on the development of novel therapeutics for cancer, and identify mechanisms for selection of treatments best suited to individual patients. It will also develop innovative strategies to identify cancer through molecular imaging techniques.
Investigating Neuroinflammation And Its Relationship With Progressive Brain Structural Loss In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$466,252.00
Summary
This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using novel brain scanning we will index whether brain cells involved in inflammation, called microglia, are in an activated state in people with schizophrenia. We expect microglia will be ‘activated’ in a subgroup of patients with schizophrenia, and will be related to progressive brain volume loss in these patients. This information will help us develop new treatme ....This project will investigate whether brain inflammation contributes to progressive brain volume loss in people with schizophrenia. Using novel brain scanning we will index whether brain cells involved in inflammation, called microglia, are in an activated state in people with schizophrenia. We expect microglia will be ‘activated’ in a subgroup of patients with schizophrenia, and will be related to progressive brain volume loss in these patients. This information will help us develop new treatments to prevent brain volume loss in the illness.Read moreRead less
Novel Radioligands For PET Imaging And Phenotyping Of Multiple Sclerosis Diagnosis
Funder
National Health and Medical Research Council
Funding Amount
$817,828.00
Summary
This project aims to catalyse a paradigm shift in the management of multiple sclerosis (MS). We will achieve this paradigm shift by developing radioligands that can be used to image the brain of MS patients. These agents will target a protein in MS patients that will be diagnostic of the state of disease progression. This will facilitate prediction of disease outcome, monitoring of therapeutic response and the development of novel treatment strategies for the better treatment of MS.